- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Type 2 diabetes mellitus (T2DM)
- Meeting Date: March 2020
- Public Summary Document (PSD) March 2020 PBAC Meeting - (PDF 831KB)
- Public Summary Document (PSD) March 2020 PBAC Meeting - (Word 167KB)
Semaglutide – March 2020
Semaglutide: Injection 2 mg in 1.5 ml pre-filled syringe; Injection 4 mg in 3 ml pre-filled syringe; Ozempic®
Last updated
3 July 2020